Personalized lymphoma therapy: could lower radiation be enough?

This trial is testing a personalized approach for people with early-stage extranodal NK/T-cell lymphoma, a rare cancer of the immune system. All participants receive two cycles of induction chemotherapy (GELAD), then doctors check how well the tumor responded using a PET/CT scan and a blood test for Epstein-Barr virus DNA. Based on that early response, patients are assigned to different treatment paths: some get standard or reduced-dose radiation, while others receive an additional immunotherapy drug called sintilimab. The goal is to see if adjusting treatment based on early response can maintain high progression-free survival while potentially reducing unnecessary radiation exposure.